Masatsugu Horiuchi Selected Research

Polyethylene (Polythene)

1/2016	Angiotensin II Type 2 Receptor Inhibits Vascular Intimal Proliferation With Activation of PPARγ.
1/2016	Synergistic Inhibitory Effect of Rosuvastatin and Angiotensin II Type 2 Receptor Agonist on Vascular Remodeling.
1/2016	Low-Protein Diet-Induced Fetal Growth Restriction Leads to Exaggerated Proliferative Response to Vascular Injury in Postnatal Life.
3/2014	Possible role of angiotensin-converting enzyme 2 and activation of angiotensin II type 2 receptor by angiotensin-(1-7) in improvement of vascular remodeling by angiotensin II type 1 receptor blockade.
7/2012	Possible involvement of angiotensin-converting enzyme 2 and Mas activation in inhibitory effects of angiotensin II Type 1 receptor blockade on vascular remodeling.
6/2012	Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E-/- mice.
5/2011	Temporary treatment with AT1 receptor blocker, valsartan, from early stage of hypertension prevented vascular remodeling.
2/2009	Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
10/2006	Attenuation of inflammatory vascular remodeling by angiotensin II type 1 receptor-associated protein.
9/2005	Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masatsugu Horiuchi Research Topics

Disease

25	Cognitive Dysfunction 04/2020 - 07/2006
19	Vascular Remodeling 10/2016 - 10/2002
18	Stroke (Strokes) 10/2018 - 11/2006
16	Hypertension (High Blood Pressure) 01/2017 - 02/2006
16	Vascular System Injuries 01/2016 - 01/2002
16	Insulin Resistance 12/2015 - 09/2002
14	Inflammation (Inflammations) 09/2013 - 11/2004
13	Atherosclerosis 06/2012 - 11/2004
11	Brain Ischemia (Cerebral Ischemia) 11/2015 - 08/2004
8	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 10/2008
8	Neointima 10/2016 - 01/2002
8	Cardiomegaly (Heart Hypertrophy) 01/2016 - 01/2002
8	Body Weight (Weight, Body) 12/2015 - 12/2006
6	Dementia (Dementias) 04/2020 - 09/2009
6	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2016 - 12/2004
6	Glucose Intolerance 02/2011 - 09/2002
5	Type 2 Diabetes Mellitus (MODY) 12/2015 - 02/2008
5	Fibrosis (Cirrhosis) 07/2013 - 01/2002
4	Infarction (Infarctions) 01/2016 - 05/2003
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2012 - 05/2007
3	Muscle Weakness 01/2021 - 01/2019
3	Brain Injuries (Brain Injury) 10/2018 - 09/2008
3	Ischemia 11/2015 - 12/2004
3	Diabetes Mellitus 05/2013 - 04/2009
3	Atherosclerotic Plaque (Atheroma) 06/2012 - 11/2004
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2012 - 01/2004
3	Hypertrophy 05/2010 - 03/2005
2	Neurologic Manifestations (Neurological Manifestations) 10/2018 - 11/2006
2	Fetal Growth Retardation (Intrauterine Growth Retardation) 03/2018 - 01/2016
2	Obesity 01/2016 - 01/2013
2	Essential Hypertension 01/2014 - 01/2011
2	Multiple Sclerosis 01/2013 - 04/2009
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2013 - 04/2009

Drug/Important Bio-Agent (IBA)

40	Angiotensin IIIBA 01/2021 - 05/2003
24	Type 2 Angiotensin ReceptorIBA 01/2019 - 05/2003
15	olmesartanIBA 10/2014 - 10/2002
15	Type 1 Angiotensin ReceptorIBA 03/2014 - 03/2005
13	AngiotensinsIBA 01/2018 - 01/2002
13	Polyethylene (Polythene)IBA 01/2016 - 08/2002
11	compound 21IBA 10/2018 - 01/2012
11	Glucose (Dextrose)FDA LinkGeneric 12/2015 - 09/2002
10	Valsartan (Vals)FDA Link 05/2011 - 01/2002
9	Superoxides (Superoxide)IBA 04/2020 - 02/2004
9	Proteins (Proteins, Gene)FDA Link 01/2016 - 03/2005
9	Messenger RNA (mRNA)IBA 01/2016 - 05/2003
9	Insulin (Novolin)FDA Link 09/2013 - 05/2004
9	ApolipoproteinsIBA 06/2012 - 11/2004
7	Telmisartan (Micardis)FDA Link 05/2012 - 01/2008
7	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 02/2011 - 02/2004
6	PPAR gammaIBA 10/2018 - 10/2008
5	Angiotensin-Converting Enzyme 2IBA 01/2020 - 11/2011
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019 - 01/2012
5	Angiotensin Receptor AntagonistsIBA 09/2015 - 12/2006
5	Antihypertensive Agents (Antihypertensives)IBA 04/2014 - 02/2009
5	Nifedipine (Adalat)FDA LinkGeneric 01/2014 - 01/2006
5	Angiotensin II Type 1 Receptor BlockersIBA 05/2012 - 12/2006
4	angiotensin I (1-7)IBA 01/2020 - 07/2012
4	2-chloro-5-nitrobenzanilideIBA 10/2018 - 10/2008
4	CytokinesIBA 01/2017 - 06/2012
4	LipidsIBA 01/2016 - 11/2004
4	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2015 - 02/2004
4	Apolipoproteins E (ApoE)IBA 06/2012 - 09/2005
4	ReninIBA 05/2011 - 02/2009
4	Estrogens (Estrogen)FDA Link 03/2011 - 01/2002
4	CholesterolIBA 01/2008 - 01/2003
4	azelnidipineIBA 12/2006 - 02/2004
3	Amyloid (Amyloid Fibrils)IBA 04/2020 - 02/2012
3	NADP (NADPH)IBA 04/2020 - 06/2012
3	NADPH Oxidases (NAD(P)H oxidase)IBA 04/2020 - 02/2004
3	Monocyte Chemoattractant ProteinsIBA 04/2020 - 01/2006
3	EnzymesIBA 01/2018 - 10/2014
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2017 - 09/2002
3	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2017 - 01/2013
3	SaltsIBA 11/2016 - 12/2007
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2016 - 11/2012
3	azilsartanIBA 04/2015 - 05/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 02/2004
3	AldosteroneIBA 09/2013 - 05/2003
3	CollagenIBA 07/2013 - 08/2009
3	DNA (Deoxyribonucleic Acid)IBA 01/2012 - 08/2002
3	AngiotensinogenIBA 05/2011 - 02/2009
3	candesartanIBA 12/2007 - 09/2006
2	Receptor for Advanced Glycation End ProductsIBA 04/2020 - 10/2007
2	Interferon Regulatory Factor-1 (Interferon Regulatory Factor 1)IBA 10/2018 - 10/2016
2	salicylhydroxamic acid (SHAM)IBA 01/2018 - 11/2015
2	Peptides (Polypeptides)IBA 01/2017 - 01/2016
2	Pharmaceutical PreparationsIBA 09/2016 - 01/2014
2	Rosuvastatin Calcium (Crestor)FDA Link 01/2016 - 11/2012
2	NAD (NADH)IBA 01/2016 - 02/2004
2	Matrix Metalloproteinases (MMPs)IBA 07/2013 - 06/2012
2	Irbesartan FDA LinkGeneric 11/2012 - 03/2011
2	propagermanium (Ge 132)IBA 11/2012 - 06/2011
2	Oxidoreductases (Dehydrogenase)IBA 06/2012 - 11/2004
2	LigandsIBA 01/2012 - 10/2007
2	Biomarkers (Surrogate Marker)IBA 12/2011 - 04/2011
2	Neuroprotective AgentsIBA 03/2011 - 12/2004
2	Losartan (Cozaar)FDA LinkGeneric 08/2010 - 10/2008
2	p38 Mitogen-Activated Protein KinasesIBA 05/2010 - 10/2008

Therapy/Procedure

2	Oral Administration 01/2017 - 12/2007
2	Ligation 06/2012 - 05/2003